ESLA · Estrella Immunopharma, Inc.
Estrella Immunopharma Inc (ESLA)
What's happening
- ESLA is up 35.47% today, trading at $0.54. — Live quote
- Volume today (24,394) is well below its 3-month average of 1,041,560. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.35 actual vs. $-0.18 estimated (-90.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-08-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $45.4M | $47.7M | $43.9M | $35.5M | $32.6M |
| P/E | -3.04 | -3.23 | -2.78 | -2.37 | -3.29 |
| Price/Book | -6.11 | -9.05 | -4.47 | -5.82 | -17.81 |
| ROE | 201.10% | 279.73% | 160.90% | 245.74% | 540.79% |
| ROA | -819.02% | -403.11% | -449.18% | -502.49% | -405.10% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-08; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -79.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ESLA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$2.1M | -$2.3M | -$4.8M | -$5.5M | -$2.1M | -$3.4M | -$3.9M | -$469.5K |
| Net income | -$2.3M | -$2.3M | -$4.8M | -$5.5M | -$2.1M | -$3.4M | -$4.0M | -$469.5K |
| EPS (diluted) | $-0.05 | $-0.05 | $-0.13 | $-0.15 | $-0.06 | $-0.09 | $-0.11 | $-0.01 |
| EPS (basic) | $-0.05 | $-0.05 | $-0.13 | $-0.15 | $-0.06 | $-0.09 | $-0.11 | $-0.01 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.8M | $3.7M | $3.2M | $3.5M | $3.0M | $2.4M | $3.1M | $3.7M |
| Total liabilities | $9.3M | $8.9M | $13.5M | $13.4M | $9.1M | $4.3M | $3.0M | $3.0M |
| Stockholders' equity | -$7.4M | -$5.3M | -$10.4M | -$9.8M | -$6.1M | -$1.8M | $143.7K | $746.3K |
| Total current assets | $1.8M | $2.2M | $1.7M | $2.0M | $1.5M | $944.3K | $1.6M | $2.2M |
| Total current liabilities | $9.3M | $8.9M | $13.5M | $13.4M | $9.1M | $4.3M | $3.0M | $3.0M |
| Cash & equivalents | $100.0K | — | $1.4M | $1.6M | $1.3M | $421.5K | $916.9K | $1.8M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Accrued liabilities | — | — | $12.4M | $12.9M | $8.8M | — | $2.8M | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $4.4K | $4.3K | $3.8K | $3.8K | $3.8K | $3.7K | $3.7K | $3.7K |
| Retained earnings | -$41.6M | -$39.3M | -$37.0M | -$36.4M | -$31.6M | -$26.0M | -$23.9M | -$22.9M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$6.7M | -$177.5K | -$727.3K | -$414.9K | -$466.0K | -$3.1M | -$2.2M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | $4 | $7.2M | -$64.8K | $1.0M | $1.3M | -$29.5K | -$135.0K | -$150.5K |
| Share-based compensation | $145.3K | $146.7K | $459.9K | $152.4K | $159.1K | $159.1K | $432.3K | — |
| Deferred income taxes | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Jun '24 | Jun '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$13.1M | -$7.3M | -$11.1M | -$1.6M | -$249.1K |
| Net income | -$13.1M | -$7.3M | -$11.1M | -$996.1K | -$247.7K |
| EPS (diluted) | $-0.35 | $-0.27 | $-36.35 | — | — |
| EPS (basic) | $-0.35 | $-0.27 | $-36.35 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Jun '24 | Jun '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $3.2M | $3.1M | $4.5M | $3.0M | $9.7M |
| Total liabilities | $13.5M | $3.0M | $180.7K | $9.8M | $2.7M |
| Stockholders' equity | -$10.4M | $143.7K | $4.3M | -$11.7M | -$2.3M |
| Total current assets | $1.7M | $1.6M | $4.5M | $2.8M | $52.4K |
| Total current liabilities | $13.5M | $3.0M | $180.7K | $9.8M | $1.1M |
| Cash & equivalents | $1.4M | $916.9K | $4.2M | $2.5M | $40.8K |
| Accrued liabilities | $12.4M | $2.8M | — | — | — |
| Other non-current liabilities | — | — | — | $12.7K | — |
| Common stock & paid-in capital | $3.8K | $3.7K | $3.7K | $98 | $142 |
| Retained earnings | -$37.0M | -$23.9M | -$19.5M | -$12.2M | -$2.3M |
Cash flow
| Line item | Dec '25 | Jun '24 | Jun '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$1.8M | -$16.1M | -$1.3M | -$1.0M | -$316.2K |
| Investing cash flow | — | $5.0M | -$273.1K | $36.2M | -$45.2M |
| Financing cash flow | $2.3M | $12.8M | — | -$35.6M | $46.0M |
| Share-based compensation | $619.0K | $1.2M | $409.6K | — | — |
| Deferred income taxes | — | — | — | $29.5K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ESLA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 14 most recent filings · covers 2022-03-04 to 2026-08-25
Recent transactions
- Most recent: Liu Cheng (CEO) — Option exercise of 100,000 shares on 2026-08-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Liu Cheng | CEO | Option exercise | 2026-08-25 | 100,000 |
| Xu Jiandong | Chief Financial Officer | Option exercise | 2026-08-18 | 100,000 |
| Owl Creek Asset Management, L.P. | 10% owner | Other acquisition/disposition | 2023-09-29 | 255,000 |
| Li Jianwei | Co-Chief Executive Officer | Open market purchase | 2022-03-04 | 141,970 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-25 | Liu Cheng | CEO | Option exercise | 100,000 | $0.81 |
| 2026-08-18 | Xu Jiandong | Chief Financial Officer | Option exercise | 100,000 | $0.81 |
| 2025-10-07 | Xu Jiandong | Chief Financial Officer | Open market purchase | 1,000 | $1.33 |
| 2025-09-22 | Xu Jiandong | Chief Financial Officer | Open market purchase | 1,000 | $1.16 |
| 2025-09-11 | Xu Jiandong | Chief Financial Officer | Open market purchase | 100 | $1.04 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:29 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-08 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-25 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-21 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-05-18 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-29 | 4 | 2025-09-11 | View on SEC.gov → |
| 2026-03-18 | 10-K | 2025-12-31 | View on SEC.gov → |
| 2026-01-13 | 8-K | 2026-01-07 | View on SEC.gov → |
| 2026-01-06 | 8-K | 2026-01-05 | View on SEC.gov → |
| 2025-12-04 | 8-K | 2025-12-04 | View on SEC.gov → |
Recent news
Headlines about ESLA (Estrella Immunopharma, Inc.). Links open the publisher — we don’t host full articles.
-
Estrella Immunopharma Shares Rise 17.91% After Hours - Estrella Immunopharma (NASDAQ:ESLA)
Benzinga · 2026-10-22 -
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ
www.timothysykes.com · 2026-10-21 -
Top Movers: US Session Features Double-Digit Gainers and Losers
ChartMill · 2026-10-21 -
Postmarket Movers: Oct. 19 After-Hours Gainers and Losers
ChartMill · 2026-10-19 -
Today's Top US Stock Movers: Small-Cap Gainers and Losers
ChartMill · 2026-10-19 -
Today's Top Market Movers: Silence Therapeutics Jumps 126%, CL Workshop Slides 43%
ChartMill · 2026-10-19 -
Gap-Up and Gap-Down Movers for Oct. 19, 2026
ChartMill · 2026-10-19 -
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 2026-10-19
No headlines in this category right now — try “All”.